However, as CD16 expression on γδ T cells is weaker than on NK cells, and CD19 is often expressed at lower levels on target lymphoma cells than CD20 [5, 20], it was important to confirm that these immune cells can indeed serve as effector cells for tafasitamab, especially against primary lymphoma cells. This evidence concerns the gene FCGR3A and lymphoma.